If you have been reading about analytical characterisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
=== Hybridization === In northern Spain C. brunneus and C. jacobsi form a hybrid zone. It has been suggested that the two species diverged during Pleistocene ice age. Both have the same number of chromosomes (2n=17) with three pairs of long metacentric, four pairs of medium acrocentric, and one pair of short acrocentric chromosomes. Using in situ hybridization an extra rDNA sequence is consistently found on the X chromosome in C. brunneus that is absent in C. jacobsi. The additional rDNA is not expressed in either C. brunneus or the hybrids that possess the rDNA sequence. C. brunneus and C. jacobsi can also be differentiated based on song and by the difference in number of stridulatory pegs located on the hind femur. Using a mark and recapture procedure, the lifetime dispersal of C. brunneus and C. jacobsi were estimated to be similar to other grasshopper species that form hybrid zones. C. brunneus and C. jacobsi are dominant during different months. C. brunneus are dominant in August while C. jacobsi are dominant in June and July. Additionally C. brunneus are only found in valley habitats while C. jacobsi are found in both valley and mountain habitats This suggests both seasonal and temporal isolation between the two species. C. brunneus, C. jacobsi, and hybrid females all show a preference for male C. brunneus and C. jacobsi songs over hybrid male songs. Differences in song traits echeme, syllable, and phrase length have a small epistatic effect but cannot be fully explained by genetic factors.
== Early life == Daveigh Elizabeth Chase-Schwallier was born on July 24, 1990, in Las Vegas, Nevada, to Cathy Chase and John David Schwallier. She was young when her parents divorced. Each remarried, and she grew up with several half-siblings, including a younger half-brother named Cade. Chase later used her mother's maiden name professionally. She subsequently relocated with her mother to Albany, Oregon, where she performed in local talent shows and pageants. Her early vocal performances were centered on country music, for which she won a national vocal competition during her childhood. During a stay in Los Angeles, Chase began attending casting calls and booking minor roles, including national television advertising spots at age seven for the Campbell's Soup Company. Chase appeared in a regional theatrical production of the musical Utah! at the Tuacahn Amphitheatre in 1998, sharing the role of Norma Sanderson. She credited this stage experience with refining her live singing ability and performance presence.
== Wound assessment principles == Wound assessment includes observation of the wound, surveying the patient, as well as identifying relevant clinical data from physical examination and patient's health history. Clinical data recorded during an initial assessment serves as a baseline for prescribing the appropriate treatment.
Sources: en.wikipedia.org
Piston syringes were used in ancient times. During the 1st century AD Aulus Cornelius Celsus mentioned the use of them to treat medical complications in his De Medicina. 9th century: The Iraqi/Egyptian surgeon Ammar ibn 'Ali al-Mawsili' described a syringe in the 9th century using a hollow glass tube, and suction to remove cataracts from patients' eyes, a practice that remained in use until at least the 13th century. Pre-Columbian Native Americans created early hypodermic needles and syringes using "hollow bird bones and small animal bladders". 1650: Blaise Pascal invented a syringe (not necessarily hypodermic) as an application of what is now called Pascal's law. 1844: Irish physician Francis Rynd invented the hollow needle and used it to make the first recorded subcutaneous injections, specifically a sedative to treat neuralgia. 1853: Charles Pravaz and Alexander Wood independently developed medical syringes with a needle fine enough to pierce the skin. Pravaz's syringe was made of silver and used a screw mechanism to dispense fluids. Wood's syringe was made of glass, enabling its contents to be seen and measured, and used a plunger to inject them. It is effectively the syringe that is used today. 1865: Charles Hunter coined the term "hypodermic", and developed an improvement to the syringe that locked the needle into place so that it would not be ejected from the end of the syringe when the plunger was depressed, and published research indicating that injections of pain relief could be given anywhere in the body, not just in the area of pain, and still be effective.
Ions in salts are primarily held together by the electrostatic forces between the charge distribution of these bodies, and in particular, the ionic bond resulting from the long-ranged Coulomb attraction between the net negative charge of the anions and net positive charge of the cations. There is also a small additional attractive force from van der Waals interactions which contributes only around 1–2% of the cohesive energy for small ions. When a pair of ions comes close enough for their outer electron shells (most simple ions have closed shells) to overlap, a short-ranged repulsive force occurs, due to the Pauli exclusion principle. The balance between these forces leads to a potential energy well with minimum energy when the nuclei are separated by a specific equilibrium distance. If the electronic structure of the two interacting bodies is affected by the presence of one another, covalent interactions (non-ionic) also contribute to the overall energy of the compound formed. Salts are rarely purely ionic, i.e. held together only by electrostatic forces. The bonds between even the most electronegative/electropositive pairs such as those in caesium fluoride exhibit a small degree of covalency. Conversely, covalent bonds between unlike atoms often exhibit some charge separation and can be considered to have a partial ionic character. The circumstances under which a compound will have ionic or covalent character can typically be understood using Fajans' rules, which use only charges and the sizes of each ion.
Rhodesian Bush War historical research / discussion forum Ironing the lawn in Salisbury – the last days of Rhodesia (The Guardian) 1975 BBC report on the failure of negotiations between the Rhodesian government and the black nationalists The Brookings Institution : Managing Ethnic Conflict in Africa – Rhodesia/Zimbabwe Selby, Angus (2006) "Commercial Farmers and the State: Interest Group Politics and Land Reform in Zimbabwe, 1890–2005", PhD Thesis, Oxford University Rhodesia Roll of Honour – Those who died in defence of UDI Rhodesian aviation and comment Window on Rhodesia – history archive
Sources: en.wikipedia.org
=== Rare causes of cholestasis === The causes of cholestasis are diverse, and some feature more prominently than others. Some rare causes include primary sclerosing cholangitis, primary biliary cholangitis, familial intrahepatic cholestasis, Alagille syndrome, sepsis, total parenteral nutrition-based cholestasis, benign recurrent intrahepatic cholestasis, biliary atresia, and intrahepatic cholestasis of pregnancy.
==== United States ==== DOPR is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Beef Products Inc. – official website "Have you ever used so-called 'pink slime' in your burgers?". McDonald's official website. "Do you use so-called 'pink slime' or 'pink goop' in your Chicken McNuggets?". McDonald's official website.
==== Myosin storage myopathy ==== In myosin storage myopathies, myosin accumulates beneath sarcolemma and between myofibrils, forming protein aggregates. A myopathy associated with the gene MYH7 is autosomal dominant myosin storage congenital myopathy-7A (CMYP7A).
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.